nafamostat has been researched along with Heart Failure in 4 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We concluded that platelet-activating factor may play a critical role in the development of severe heart failure with left ventricular assistance, and nafamostat administration is likely to be beneficial in such a critical condition by suppressing the platelet-activating factor level." | 7.70 | Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure. ( Fukui, K; Koyama, M; Munakata, M; Ono, Y; Satoh, K; Suzuki, S, 2000) |
| "We concluded that platelet-activating factor may play a critical role in the development of severe heart failure with left ventricular assistance, and nafamostat administration is likely to be beneficial in such a critical condition by suppressing the platelet-activating factor level." | 3.70 | Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure. ( Fukui, K; Koyama, M; Munakata, M; Ono, Y; Satoh, K; Suzuki, S, 2000) |
| " We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute cardiac or respiratory failure." | 1.37 | Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation. ( Han, SJ; Hong, KS; Kim, HS; Kim, KI; Lee, SH; Lee, WK; Whang, SM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, SJ | 1 |
| Kim, HS | 1 |
| Kim, KI | 1 |
| Whang, SM | 1 |
| Hong, KS | 1 |
| Lee, WK | 1 |
| Lee, SH | 1 |
| Sawaki, D | 1 |
| Otani, Y | 1 |
| Kobayakawa, N | 1 |
| Sekita, G | 1 |
| Fukushima, K | 1 |
| Takeuchi, H | 1 |
| Ogawa, T | 1 |
| Takemura, T | 1 |
| Aoyagi, T | 1 |
| Ihno, T | 1 |
| Nakagawa, T | 1 |
| Furukawa, H | 1 |
| Shimizu, K | 1 |
| Egi, K | 1 |
| Maemura, T | 1 |
| Motomiya, T | 1 |
| Munakata, M | 1 |
| Ono, Y | 1 |
| Koyama, M | 1 |
| Fukui, K | 1 |
| Satoh, K | 1 |
| Suzuki, S | 1 |
4 other studies available for nafamostat and Heart Failure
| Article | Year |
|---|---|
Use of nafamostat mesilate as an anticoagulant during extracorporeal membrane oxygenation.
Topics: Acute Disease; Anticoagulants; Benzamidines; Dose-Response Relationship, Drug; Extracorporeal Membra | 2011 |
A case of heparin-induced thrombocytopenia with sepsis and congestive heart failure--first autopsy report on Japan--.
Topics: Aged; Aged, 80 and over; Antibodies; Benzamidines; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; | 2004 |
Various problems during long-term percutaneous cardiopulmonary support.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Benzamidines; Blood Transfusion, Autologous; Cardiop | 1997 |
Nafamostat mesilate modulates the release of platelet-activating factor during left ventricular assistance with hemofiltration in canine heart failure.
Topics: Animals; Antithrombins; Benzamidines; Dogs; Guanidines; Heart Failure; Heart-Assist Devices; Hemofil | 2000 |